During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.

In terms of NCCN guidelines, for low-risk patients, there's monitoring, there's assessment for disease progression, but there's also symptomatic monitoring. For those patients, it is a reasonable ...

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and efficacy.

Shifting from a tumor-centric to a patient-centric approach is crucial for older patients with cancer, focusing on functional ...

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable ...

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in ...

High Ki-67 expression predicts poorer survival in patients with acral melanoma, a rare subtype in which Ki-67's predictive ...

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for ...

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from ...

Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to ...

Binod Dhakal, MD, discusses using a variety of combination therapies as bridging or later-line options for patients with relapsed myeloma.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near ...